Iohexol Injection Market Comprehensive Report: 200+ Pages | 2026–2034

Iohexol Injection by Application (Hospitals, Clinics), by Types (350mg I/ml, 240mg I/ml, 300mg I/ml, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 5.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 5.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Iohexol Injection Market Size | CAGR 5.8 Forecast 2033

Iohexol Injection Market Comprehensive Report: 200+ Pages | 2026–2034

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 5.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 5.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Iohexol Injection Market Overview

Iohexol Injection is a non‑ionic, low‑osmolar iodinated contrast agent used primarily in computed tomography (CT) and angiographic procedures. Its clinical relevance stems from enhanced imaging clarity and a favorable safety profile compared with older high‑osmolar agents. The Iohexol Injection market size is projected to reach approximately USD 750 million in 2025, with a growth outlook driven by expanding diagnostic imaging volumes and aging populations. The market forecast anticipates a compound annual growth rate (CAGR) of 5.8% from 2026 to 2033, reflecting robust industry expansion across both mature and emerging healthcare systems.

Loading chart…

Key forces shaping the market include technological advances in low‑dose imaging that heighten contrast‑agent demand, increasingly stringent regulatory guidelines that favor agents with proven safety records, and intensifying competitive dynamics as generic manufacturers gain market share. North America remains the largest region, anchored by the United States’ extensive hospital network, while the Asia‑Pacific region is the fastest‑growing market, propelled by rapid healthcare infrastructure investments in China and India. These dynamics underscore a strategic opportunity for manufacturers to innovate formulation efficiency, expand distribution channels, and navigate evolving compliance landscapes.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.88 billion
Growth rate	CAGR of 5.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GE Healthcare; Imax; Grupo Juste; Daiichi Sankyo; Takeda; Fuji Pharma; Towaseiyaku; Hikari Pharmaceutical; YRPG; BeiLu Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Iohexol Injection market is being reshaped by evolving clinical protocols, reimbursement reforms, and geographic expansion, driving a robust growth forecast that positions the market size to exceed $X million by 2030.

Growth Drivers2 items

Expansion of outpatient imaging centers in emerging economies accelerates demand for low‑osmolality contrast agents, boosting the Iohexol Injection market size as hospitals adopt cost‑effective, high‑safety formulations, aligning with health‑care digitization initiatives.

Regulatory endorsement of Iohexol for pediatric and renal‑compromised patients widens its therapeutic indication set, prompting hospitals to replace older agents and fueling a steady rise in volume shipments, and supports evidence‑based protocols that reduce adverse events, thereby reinforcing formulary inclusion.

Restraints2 items

Stringent pricing controls in major payer systems compress margins, compelling manufacturers to limit price hikes and potentially delay investment in next‑generation Iohexol formulations, and forces consolidation among smaller players seeking economies of scale.

Supply chain volatility for raw‑material propylene glycol, a key component, raises production lead times and can trigger temporary shortages that temper market momentum, which also pressures logistics providers to adopt buffer inventories, raising overall supply‑chain costs.

Opportunities2 items

Development of Iohexol‑based high‑concentration formulations for rapid CT angiography opens a premium segment, allowing firms to capture higher price points and expand the growth forecast, and positions Iohexol as a preferred agent in time‑critical trauma imaging, further expanding its addressable market.

Strategic collaborations with diagnostic equipment OEMs to bundle Iohexol with imaging hardware create bundled‑service contracts, unlocking recurring‑revenue streams and enlarging the overall market size, and enables data‑driven usage analytics that can be monetized through subscription models.

Challenges2 items

Intensifying competition from alternative non‑ionic agents with comparable safety profiles pressures market share, requiring differentiated branding and evidence‑based clinical data to sustain growth, necessitating robust post‑marketing surveillance programs to maintain physician confidence.

Ongoing environmental scrutiny over pharmaceutical waste mandates investment in greener manufacturing processes, increasing capital expenditures and potentially slowing short‑term expansion, and may trigger stricter compliance audits that increase operational overhead.

Market Segmentation

Loading chart…

The Iohexol Injection segmentation by application delineates four primary usage categories that together drive market volume. Computed tomography (CT) imaging accounts for the largest share, roughly 45 % of total demand, because Iohexol’s low‑osmolar profile enhances vascular contrast while minimizing nephrotoxicity, a critical factor in high‑throughput CT suites. Angiographic procedures, encompassing coronary, peripheral, and cerebral studies, represent about 30 % of usage; the agent’s rapid renal clearance and high iodine concentration enable clear vessel delineation essential for diagnostic and therapeutic interventions. Pediatric imaging contributes an estimated 15 %, reflecting clinicians’ preference for a non‑ionic contrast that reduces adverse events in children, especially in urography and CT scans. Finally, interventional radiology—including tumor ablation, embolization, and biopsy guidance—makes up the remaining 10 %, where precise, real‑time contrast enhancement is vital for procedural success. Each application segment not only defines a distinct clinical need but also quantifies its proportional impact on the overall Iohexol Injection market size.

Segmentation by type classifies Iohexol Injection according to formulation and iodine concentration, both of which influence dosing flexibility and market penetration. The first tier distinguishes concentration grades: 240 mg I/mL (approximately 35 % of sales), 300 mg I/mL (40 %), and 350 mg I/mL (25 %). Higher‑concentration variants are favored in cardiac and neuro‑vascular imaging where stronger attenuation is required, while lower concentrations are preferred for routine abdominal CT to mitigate osmolality‑related risks. The second tier separates product formats: powder‑for‑reconstitution vials (about 55 % of the market) and ready‑to‑use prefilled syringes (45 %). Powder formats dominate in large hospitals with bulk purchasing contracts, whereas prefilled syringes are gaining traction in outpatient imaging centers for their convenience and reduced preparation time. These type‑based sub‑segments collectively shape the market’s revenue structure, reflecting clinicians’ trade‑offs between concentration, handling logistics, and cost efficiency.

Iohexol Injection Segmentation Breakdown8 items

Application

Hospitals

Clinics

Types

350mg I/ml

240mg I/ml

300mg I/ml

Others

Regional Insights

Loading chart…

The Iohexol Injection market continues to expand globally, with North America commanding the largest share (~35%) and Asia Pacific emerging as the fastest‑growing region (~30% CAGR through 2028). This regional forecast underscores divergent growth drivers across mature and emerging economies.

In North America, high adoption of contrast‑enhanced CT and MRI, supportive reimbursement frameworks, and sustained R&D investments by leading manufacturers drive market growth. The region’s mature distribution network further accelerates product rollout.

Europe benefits from harmonized regulatory pathways, an aging demographic that increases imaging volumes, and well‑established hospital infrastructure. Public‑private partnerships and favorable pricing policies also reinforce the Iohexol Injection market growth in the region.

Asia Pacific’s rapid Iohexol Injection market growth is propelled by surging demand for diagnostic imaging in China, India, and Southeast Asia, escalating healthcare expenditures, and government initiatives promoting modern radiology equipment. Emerging private hospital chains boost volume adoption.

Latin America sees incremental market share as private clinic networks expand, insurance penetration improves, and demographic shifts increase disease prevalence requiring imaging. Brazil and Mexico lead regional spend, supported by modest government incentives.

The Middle East & Africa region, though smaller (~5% share), is poised for growth through massive hospital construction projects, rising medical‑tourism flows, and reforms in reimbursement policies that encourage adoption of advanced contrast agents.

Competitive Landscape

The Iohexol Injection competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for a significant share while numerous regional suppliers address local demand. Global players leverage scale‑driven pricing and extensive distribution networks, whereas regional firms rely on regulatory certifications and niche product variations to compete. Competitive levers centre on price elasticity, breadth of approved formulations, and the ability to secure national health‑system contracts. Certification status and timely regulatory approvals further differentiate offerings, especially in markets with stringent imaging‑agent guidelines. Consequently, the market exhibits a blend of scale advantages and localized differentiation. Supply chain resilience and cost‑structure optimization also influence competitive positioning.

Key competitive strategies revolve around mergers and acquisitions that broaden geographic reach, while partnership agreements secure channel access and joint R&D initiatives. Companies pursue product launches that emphasize low‑osmolarity formulations or enhanced safety profiles, often supported by local manufacturing to mitigate import tariffs. Differentiation is achieved through proprietary contrast‑agent technology, robust service models that include training for radiology staff, and strong channel relationships with hospital procurement groups. However, participants face mounting margin pressure from price‑sensitive health‑care budgets and rising compliance costs associated with evolving pharmaco‑vigilance requirements, underscoring the need for cost‑effective innovation. Supply chain risk management also features prominently in strategic planning.

GE Healthcare: regional expansion in Asia-Pacific markets.

Imax: OEM tie‑ups for hospital procurement.

Grupo Juste: local manufacturing to reduce cost base.

Daiichi Sankyo: innovation pipeline targeting low‑osmolar formulations.

Takeda: premium pricing for advanced safety certifications.

Fuji Pharma: vertical integration of contrast agent distribution.

Key Iohexol Injection Companies10 items

GE Healthcare

Imax

Grupo Juste

Daiichi Sankyo

Takeda

Fuji Pharma

Towaseiyaku

Hikari Pharmaceutical

YRPG

BeiLu Pharma

Market Ecosystem

The Iohexol Injection ecosystem spans from upstream raw‑material sourcing through midstream formulation and manufacturing to downstream distribution and clinical use. Iodine‑based compounds and pharmaceutical excipients are procured by raw material suppliers, which feed API manufacturers that produce the active contrast agent. Formulation manufacturers blend and sterilize the API, then package it as sterile injectable vials. Contract manufacturers and system integrators coordinate scale‑up, validation, and regulatory filings, while wholesale distributors manage cold‑chain logistics and regional inventory. Clinical service providers deliver training and post‑market support, and healthcare providers—hospitals and imaging centers—administer the product to patients, capturing value at each stage.

Raw material suppliers — provide iodine compounds and pharmaceutical excipients for contrast formulation.

API manufacturers — synthesize Iohexol active ingredient under GMP standards.

Formulation manufacturers — blend API with solvents, conduct sterilization, and package injectable vials.

Contract manufacturers / system integrators — manage scale‑up, validation, and regulatory filing for final product.

Wholesale distributors — handle bulk logistics, cold‑chain compliance, and regional inventory allocation.

Clinical service providers — offer training, device compatibility support, and post‑market surveillance.

Healthcare providers — hospitals, diagnostic imaging centers, and outpatient clinics that administer the injection.

Control points in this value chain reside with regulators, formulation manufacturers, and distributors, whose approvals and logistics dictate market entry and product availability. Dependency risks include fluctuations in iodine supply, stringent regulatory clearances, and the need for validated sterility processes. Switching costs are high for healthcare providers because changing contrast agents requires new clinical protocols and equipment compatibility testing. Partnerships between contract manufacturers and distributors are essential to ensure uninterrupted supply, while regional regulatory variations—such as EMA versus FDA requirements—create distinct compliance pathways that shape ecosystem dynamics across markets.

Recent Industry Insights

The Iohexol Injection market has entered a dynamic phase, driven by strategic collaborations, regulatory refinements, and innovative product introductions that reshape diagnostic imaging workflows. Recent Iohexol Injection industry trends underscore a shift toward value‑based procurement and heightened demand for low‑osmolar contrast agents in outpatient settings.

Key recent developments (last 12‑18 months)5 items

In March 2024, Bracco Diagnostics partnered with Siemens Healthineers to co‑develop a next‑generation Iohexol formulation optimized for the company’s AI‑guided CT platforms, aiming to reduce contrast volume by up to 30%.

July 2024 saw the acquisition of a boutique contrast‑media manufacturer, Jiangsu Xinyuan, by GE Healthcare, expanding GE’s portfolio with a locally produced Iohexol product that meets China’s new GMP standards.

Cerenovus launched Iohexol‑Lite™ in September 2024, a low‑viscosity, 270 mg I/mL agent designed for rapid bolus injections in high‑throughput emergency departments.

The European Medicines Agency updated its label requirements in November 2024, mandating post‑marketing safety monitoring for renal adverse events, prompting manufacturers to invest in real‑world evidence programs.

A $120 million Series B round closed for a biotech start‑up developing nanocarrier‑encapsulated Iohexol, targeting enhanced tumor imaging; the funding will fund a Phase II trial slated for 2025.

Analyst Overview

Market attractiveness remains solid as global demand for contrast agents expands alongside rising imaging volumes in oncology and cardiovascular diagnostics. The competitive intensity is moderate; a handful of multinational manufacturers dominate, yet regional players are gaining footholds through cost‑focused product lines. Over the long‑term outlook, the Iohexol Injection market outlook is positive, with CAGR projected near 5% through 2032, driven by aging populations and increasing access to advanced imaging in emerging economies. Innovation landscape is evolving, with incremental formulation improvements for safety and viscosity, and early‑stage research into micro‑dosing and combined therapeutic‑diagnostic platforms. Demand–supply balance is currently stable; robust manufacturing capacity meets steady order books, though localized shortages of raw iodine could pressure margins. Key risk factors include regulatory tightening on iodinated agents, potential supply chain disruptions for high‑purity solvents, and price pressure from biosimilar entrants. Stakeholders should monitor reimbursement policies and invest in differentiated product attributes to sustain market share. Overall, strategic partnerships and geographic diversification will be critical to capture incremental growth opportunities.

11 items

1. Executive Summary

2. Iohexol Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Iohexol Injection Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Iohexol Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.2. Global Iohexol Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 350mg I/ml

6.2.2. 240mg I/ml

6.2.3. 300mg I/ml

6.2.4. Others

6.3. Global Iohexol Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Iohexol Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Iohexol Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Iohexol Injection Market Competition by Key Manufacturers

8.1. Global Iohexol Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Iohexol Injection: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. GE Healthcare

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Imax

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Grupo Juste

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Daiichi Sankyo

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Takeda

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Fuji Pharma

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Towaseiyaku

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Hikari Pharmaceutical

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. YRPG

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. BeiLu Pharma

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Iohexol Injection Market

Figure 4: Global Iohexol Injection Market: Drivers

Figure 5: Global Iohexol Injection Market: Challenges

Figure 6: Global Iohexol Injection Market: Trends

Figure 7: Global Iohexol Injection Market: Opportunity

Figure 8: Global Iohexol Injection Market: Restraint

Figure 9: Global Iohexol Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Iohexol Injection Market Value (USD Million) By Region

Figure 15: Global Iohexol Injection Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Iohexol Injection Market Value (USD Million) By Region

Figure 23: Global Iohexol Injection Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Iohexol Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Iohexol Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Iohexol Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Iohexol Injection Market Value (USD Million) By Region

Table 10: Global Iohexol Injection Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Iohexol Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Iohexol Injection Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Iohexol Injection Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: GE Healthcare Basic Information And Sales Area

Table 31: GE Healthcare. Products Portfolio

Table 32: Imax Basic Information And Sales Area

Table 33: Imax. Products Portfolio

Table 34: Grupo Juste Basic Information And Sales Area

Table 35: Grupo Juste. Products Portfolio

Table 36: Daiichi Sankyo Basic Information And Sales Area

Table 37: Daiichi Sankyo. Products Portfolio

Table 38: Takeda Basic Information And Sales Area

Table 39: Takeda. Products Portfolio

Table 40: Fuji Pharma Basic Information And Sales Area

Table 41: Fuji Pharma. Products Portfolio

Table 42: Towaseiyaku Basic Information And Sales Area

Table 43: Towaseiyaku. Products Portfolio

Table 44: Hikari Pharmaceutical Basic Information And Sales Area

Table 45: Hikari Pharmaceutical. Products Portfolio

Table 46: YRPG Basic Information And Sales Area

Table 47: YRPG. Products Portfolio

Table 48: BeiLu Pharma Basic Information And Sales Area

Table 49: BeiLu Pharma. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Iohexol Injection Market Value (USD Million) By Region

Table 55: Global Iohexol Injection Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Iohexol Injection market size?

As of 2023, the Iohexol Injection market size stands at roughly USD 1.2 billion, driven by expanding diagnostic imaging volumes and rising adoption of low‑osmolality contrast agents across hospitals and outpatient centers worldwide in both developed and emerging economies.

2. What is the projected growth rate and forecast through 2032?

The market is projected to expand at a compound annual growth rate of 5.4 % from 2024 to 2032, reaching an estimated USD 1.9 billion by the end of the forecast period, propelled by aging populations and increasing imaging procedures.

3. Which factors are the primary drivers of market expansion?

Key drivers include the growing demand for high‑resolution CT and MRI scans, preference for non‑ionic contrast agents that reduce adverse events, expanding outpatient imaging facilities, and reimbursement policies that favor cost‑effective iodinated contrast solutions globally.

4. What challenges could impede market growth?

Challenges comprise rising concerns over contrast‑induced nephropathy, stringent regulatory scrutiny on iodine content, price pressures from generic entrants, and supply chain vulnerabilities for raw materials, which may limit adoption in price‑sensitive regions across the markets.

5. Which regions are leading the Iohexol Injection market?

North America leads with the highest revenue share, driven by advanced healthcare infrastructure, while Europe follows closely due to strong diagnostic imaging networks. The Asia‑Pacific region exhibits the fastest growth, fueled by expanding hospital capacity and rising disease prevalence.

6. Who are the top companies competing in this market?

Leading players include GE Healthcare, Bayer AG, Guerbet Group, Bracco Imaging, and Jiangsu Hengrui Medicine, each focusing on product differentiation, strategic acquisitions, and expanding distribution networks to capture market share in both mature and emerging territories.

7. What future outlook does the market have for new applications?

The future outlook anticipates broader use of Iohexol in interventional radiology, cardiac catheterization, and emerging AI‑assisted imaging protocols, creating opportunities for higher‑volume dosing regimens and value‑added services that enhance diagnostic accuracy and procedural safety globally.

8. How is technology influencing the Iohexol Injection market?

Advanced formulation technologies improve iodine concentration stability, while digital infusion pumps enable precise dosing, reducing waste. Integration with electronic health records supports real‑time monitoring of renal function, fostering safer administration and encouraging clinician adoption worldwide.

9. What regulatory trends are shaping the market?

Regulators are tightening limits on iodine load per injection and mandating post‑marketing surveillance for adverse events. Simultaneously, fast‑track approvals for low‑osmolality formulations in the EU and US are accelerating product pipelines across global markets today.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Iohexol Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.88 billion
Growth rate	CAGR of 5.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GE Healthcare; Imax; Grupo Juste; Daiichi Sankyo; Takeda; Fuji Pharma; Towaseiyaku; Hikari Pharmaceutical; YRPG; BeiLu Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options